Intramuscular lipid content is increased in obesity and decreased by weight loss.
B H Goodpaster, R Theriault, S C Watkins...
https://pubmed.ncbi.nlm.nih.gov/10778870/Actively Recruiting
Led by Pennington Biomedical Research Center · Updated on 2026-08-27
50
Participants Needed
2
Research Sites
12 weeks
Total Duration
Researchers are investigating the effects of GLP-1 based therapy, specifically tirzepatide, on musculoskeletal changes after weight loss. The study focuses on adults aged 18 to 50 years with obesity or sarcopenic obesity, including underrepresented populations such as non-Hispanic Black and rural participants. The research aims to understand how tirzepatide affects muscle mass, bone density, and fat-free mass, as well as how diet and resistance-based exercise might influence these outcomes. Participants are randomly assigned to one of two groups one receiving tirzepatide along with a lifestyle toolkit that includes protein shakes and resistance exercise, and the other receiving tirzepatide with regular diet and exercise. The treatment period lasts five months, during which body composition and bone health are closely monitored. The study uses imaging techniques like DXA and MRI, along with blood markers related to bone formation and muscle health, to assess the impact of the interventions. Throughout the study, participants undergo assessments at baseline, 3 months, and 6 months including DXA scans, thigh MRI, and blood tests measuring bone and muscle-related markers. Researchers track changes in fat-free mass and muscle quality, as well as markers of bone remodeling. The total participation period lasts about six months, with safety monitoring and adherence to the prescribed lifestyle toolkit for those in the intervention group.
CONDITIONS
GLP-1R Actions on Muscle and the Skeleton
A
Adithya Hari, MD
Y
Yanna X Alesafis de Koter, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pennington Biomedical Research Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Tirzepatide and Structured Lifestyle Modification | Structured Lifestyle Modification Only |
|---|---|---|
| What it is | A combination of tirzepatide (a dual GLP-1/GIP receptor agonist) administered alongside a lifestyle toolkit, which includes two daily protein shakes and resistance exercise three times weekly. | A lifestyle toolkit made up of daily ABBOTT protein shakes and supervised resistance training three times weekly, without tirzepatide. |
| Role in the trial | Assesses the effect of tirzepatide added to lifestyle modification on muscle and bone in individuals with obesity. | Serves as the comparator, representing lifestyle modification without drug therapy for eligible adults with obesity. |
| Primary use | Investigational treatment for weight reduction, and evaluation of its effects on fat-free mass, muscle, and bone health in obesity. | Active comparator assessing lifestyle modification's effects on body composition and musculoskeletal health. |
| How it is given or performed | Tirzepatide is given by injection, frequency per product labeling; all participants receive protein shakes daily and complete supervised resistance exercise three days per week. | Participants use ABBOTT protein shakes twice daily and complete guided resistance exercise three days per week. |
| Evidence status | Randomized trials in adults with obesity show tirzepatide plus lifestyle modification leads to greater weight and fat mass loss compared to lifestyle modification alone. Effects on muscle and bone are under investigation in this trial; prior studies have not focused on musculoskeletal composition. | Lifestyle intervention with exercise and protein supplementation consistently leads to weight loss and can preserve muscle mass compared to no intervention. Results vary depending on adherence and program specifics. |
| Important limitations | Long-term effects of tirzepatide on muscle and bone have not been established. Real-world safety and adherence may differ from clinical trial conditions, and there is potential for gastrointestinal or pancreatitis risk as reported with GLP-1 based agents. | Lifestyle interventions require high participant motivation and consistent adherence, which can be challenging to achieve outside a trial setting. Effects on weight and musculoskeletal health may be less robust without structured support. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 months
Participants receive tirzepatide for 5 months and follow either a lifestyle toolkit with protein shakes and resistance exercise or regular diet and exercise.
Visits at baseline, month 3, and month 6
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
B H Goodpaster, R Theriault, S C Watkins...
https://pubmed.ncbi.nlm.nih.gov/10778870/Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad...
https://pubmed.ncbi.nlm.nih.gov/35658024/Julie R Lundgren, Charlotte Janus, Simon B K Jensen...
https://pubmed.ncbi.nlm.nih.gov/33951361/Robert L Dubin, Steven B Heymsfield, Eric Ravussin...
https://pubmed.ncbi.nlm.nih.gov/39344838/Pennington Biomedical Research Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor